Exploiting BeatAML2 dataset revealed that there were no statistically significant differences in the mRNA levels of NDUFA6, SDHA, and CYB5A in biospecimens obtained from AML patients compared to healthy BMNCs (Fig. 2A-C). This evidence concerns the gene CYB5A and acute myeloid leukemia.